Sillito, F;
Holler, A;
Stauss, HJ;
(2020)
Engineering CD4+ T Cells to Enhance Cancer Immunity.
Cells
, 9
(7)
, Article 1721. 10.3390/cells9071721.
Preview |
Text
cells-09-01721.pdf - Published Version Download (211kB) | Preview |
Abstract
This review presents key advances in combining T cell receptor (TCR) gene transfer to redirect T-cell specificity with gene engineering in order to enhance cancer-protective immune function. We discuss how emerging insights might be applied to CD4+ T cells. Although much attention has been paid to the role of CD8+ cytotoxic T cells in tumour protection, we provide convincing evidence that CD4+ helper T cells play a critical role in cancer immune responses in animal models and also in patients. We demonstrate that genetic engineering technologies provide exciting opportunities to extend the specificity range of CD4+ T cells from MHC class-II-presented epitopes to include peptides presented by MHC class I molecules. Functional enhancement of tumour immunity can improve the sensitivity of T cells to cancer antigens, promote survival in a hostile tumour microenvironment, boost cancer-protective effector mechanisms and enable the formation of T-cell memory. Engineered cancer-specific CD4+ T cells may contribute to protective immunity by a direct pathway involving cancer cell killing, and by an indirect pathway that boosts the function, persistence and memory formation of CD8+ T cells.
| Type: | Article |
|---|---|
| Title: | Engineering CD4+ T Cells to Enhance Cancer Immunity |
| Open access status: | An open access version is available from UCL Discovery |
| DOI: | 10.3390/cells9071721 |
| Publisher version: | https://doi.org/10.3390/cells9071721 |
| Language: | English |
| Additional information: | This is an open access article distributed under the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
| Keywords: | T cell receptor (TCR); T helper cell (Th); major histocompatibility complex (MHC); mechanistic target of Rapamycin 1 (mTORC1); programmed death receptor 1 (PD-1); interferon-gamma (IFN-γ) |
| UCL classification: | UCL UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Div of Infection and Immunity |
| URI: | https://discovery.ucl.ac.uk/id/eprint/10116907 |
Loading...
Loading...Loading...| 1. |  United Kingdom | 5 |
| 2. |  United States | 4 |
| 3. |  China | 3 |
| 4. |  Germany | 2 |
| 5. |  Russian Federation | 1 |
Archive Staff Only
 |
View Item |
